Adults 18 to 65, any sex, with Nonalcoholic Fatty Liver Disease (NAFLD). Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change in Intrahepatic Lipid Content Between Baseline and 6 Months as Measured by 1H-magnetic Resonance Spectroscopy (1H-MRS). Endpoints Were Assessed at Baseline and 6 Months.Primary· 6 months
Change in Intrahepatic lipid content by 1H-MRS over 6 months in the GH vs placebo group
Group
Value
95% CI
Growth Hormone
-5.2
± 10.5
Placebo
3.8
± 6.9
Change in Serum High Sensitivity C-reactive Protein (hsCRP) Between Baseline and 6 Months.Secondary· 6 months
Change in serum high sensitivity C-reactive protein (hsCRP) (mg/L) between baseline and 6 months.
Group
Value
95% CI
Growth Hormone
-0.8
± 0.9
Placebo
0.3
± 1.7
Adverse events — posted to ClinicalTrials.gov
Time frame: 6 months.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Nonalcoholic fatty liver disease (NAFLD), fatty infiltration of the liver in the absence of alcohol use, is an increasingly recognized complication of obesity, with prevalence estimates of about 30% of individuals in the United States. A subset of these will develop progressive disease in the form of nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis and liver failure. NAFLD is expected to be the most common indication for liver transplantation by the year 2020. We hypothesize that growth hormone (GH) replacement will decrease intrahepatic lipid accumulation as quantified by 1H magnetic resonance spectroscopy (1H-MRS).
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT05585177 — Growth Hormone to Improve the Clinical Outcome of Assisted Fertility in Young Patients With Decreased Ovarian Reserve
· NA
· unknown
NCT05574894 — Effect of GH Supplementation on the Blastocyst Euploid Rate in AMA Patients--A Retrospective Cohort Study
· Phase 3
· completed
NCT03966339 — Growth Hormone Adding to Controlled Ovarian Hyperstimulation for Improving Embryo Quality
· NA
· unknown
NCT03225755 — Adipose Tissue and Circulating Markers of Inflammation in GH Deficiency and Changes With GH Therapy
· completed
NCT03616509 — GH in Adults With PWS, Effect on Hypotonia Evaluated by Functional MRI, Relationship With Strength and Body Composition
· Phase 4
· completed
Other recruiting trials for Nonalcoholic Fatty Liver Disease (NAFLD)
Currently open trials in the same condition.
NCT07093346 — The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patient
· NA
· recruiting
NCT03572465 — Quantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis
· recruiting
Other Massachusetts General Hospital trials
Trials by the same sponsor.
NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis
· withdrawn
NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg
· NA
· not yet recruiting
NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior
· NA
· not yet recruiting
NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries
· NA
· not yet recruiting
NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation
· EARLY_PHASE1
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
Last refreshed: 22 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02217345.